无β-淀粉样蛋白阳性时内侧颞叶tau正电子发射断层摄取增加
这项多中心纵向队列研究汇总ADNI、HABS和AVID-A05共965名认知程度不一的老年人,发现无Aβ病理者中51%存在内侧颞叶tau PET信号增高,其tau积聚和神经退行性变进展缓慢、局限于内侧颞叶,且不伴Aβ生物标志物累积,作者认为这些个体并非朝向阿尔茨海默病的病理轨迹。
要点
- 无Aβ病理的老年人中51%存在内侧颞叶tau PET信号增高(TMTL+)。
- A- TMTL+者tau PET信号缓慢增加、局限于颞叶,不伴Aβ累积。
- A- TMTL+者内侧颞叶萎缩加速、认知下降,但速度显著慢于A+ TMTL+。
核心结论
- 无Aβ病理而内侧颞叶tau PET信号增高(A- TMTL+)者表现为tau进行性累积和神经退行性变,但过程相对缓慢、主要局限于内侧颞叶、仅伴整体认知表现的细微变化,且无Aβ生物标志物累积。
- 作者认为A- TMTL+个体并非处于朝向阿尔茨海默病的病理轨迹上。
研究设计与样本
- 多中心、观察性、纵向队列研究,汇总ADNI、HABS和AVID-A05研究2015年7月2日至2021年8月23日期间收集的数据。
- 共纳入965名认知表现程度不一的个体(503名女性,占52.1%;平均年龄73.9岁,SD 8.1岁),基线均有tau PET、Aβ PET和MRI扫描。
主要发现
- 与健康年轻对照(年龄<39岁)相比,A-个体中51%、A+参与者中78%存在内嗅皮质tau PET信号增高(TMTL+)。
- A- TMTL+者较A- TMTL-者出现具统计学显著性但程度中等的纵向tau PET增加(平均随访1.83年,SD 0.84年),主要局限于颞叶;A+ TMTL+者tau PET增加更快且皮质范围更广。
- A- TMTL+者在随访期间(平均2.36年,SD 0.76年)未见明显Aβ累积,而A+ TMTL+者不同。
- 脑脊液分析证实A- TMTL+者纵向p-tau181升高而无Aβ累积增加。
- A- TMTL+者内侧颞叶萎缩加速,A+ TMTL+者广泛颞顶叶区域萎缩加速;A-个体内侧颞叶tau PET摄取增高与认知下降相关,但速度显著慢于A+ TMTL+。
关键数值与推荐
- A-个体中51%存在内嗅皮质tau PET信号增高(TMTL+)。
- A+参与者中78%存在内嗅皮质tau PET信号增高(TMTL+)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: An increased tau positron emission tomography (PET) signal in the medial temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β (Aβ) pathology. Little is known about the longitudinal course of this condition, and its association with Alzheimer disease (AD) remains unclear. OBJECTIVE: To study the pathologic and clinical course of older individuals with PET-evidenced MTL tau deposition (TMTL+) in the absence of Aβ pathology (A-), and the association of this condition with the AD continuum. DESIGN, SETTING, AND PARTICIPANTS: A multicentric, observational, longitudinal cohort study was conducted using pooled data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Harvard Aging Brain Study (HABS), and the AVID-A05 study, collected between July 2, 2015, and August 23, 2021. Participants in the ADNI, HABS, and AVID-A05 studies (N = 1093) with varying degrees of cognitive performance were deemed eligible if they had available tau PET, Aβ PET, and magnetic resonance imaging scans at baseline. Of these, 128 participants did not meet inclusion criteria based on Aβ PET and tau PET biomarker profiles (A+ TMTL-). EXPOSURES: Tau and Aβ PET, magnetic resonance imaging, cerebrospinal fluid biomarkers, and cognitive assessments. MAIN OUTCOMES AND MEASURES: Cross-sectional and longitudinal measures for tau and Aβ PET, cortical atrophy, cognitive scores, and core AD cerebrospinal fluid biomarkers (Aβ42/40 and tau phosphorylated at threonine 181 p-tau181 available in a subset). RESULTS: Among the 965 individuals included in the study, 503 were women (52.1%) and the mean (SD) age was 73.9 (8.1) years. A total of 51% of A- individuals and 78% of A+ participants had increased tau PET signal in the entorhinal cortex (TMTL+) compared with healthy younger (aged <39 years) controls. Compared with A- TMTL-, A- TMTL+ participants showed statistically significant, albeit moderate, longitudinal (mean [SD], 1.83 [0.84] years) tau PET increases that were largely limited to the temporal lobe, whereas those with A+ TMTL+ showed faster and more cortically widespread tau PET increases. In contrast to participants with A+ TMTL+, those with A- TMTL+ did not show any noticeable Aβ accumulation over follow-up (mean [SD], 2.36 [0.76] years). Complementary cerebrospinal fluid analysis confirmed longitudinal p-tau181 increases in A- TMTL+ in the absence of increased Aβ accumulation. Participants with A- TMTL+ had accelerated MTL atrophy, whereas those with A+ TMTL+ showed accelerated atrophy in widespread temporoparietal brain regions. Increased MTL tau PET uptake in A- individuals was associated with cognitive decline, but at a significantly slower rate compared with A+ TMTL+. CONCLUSIONS AND RELEVANCE: In this study, individuals with A- TMTL+ exhibited progressive tau accumulation and neurodegeneration, but these processes were comparably slow, remained largely restricted to the MTL, were associated with only subtle changes in global cognitive performance, and were not accompanied by detectable accumulation of Aβ biomarkers. These data suggest that individuals with A- TMTL+ are not on a pathologic trajectory toward AD.
引用
- Costoya-Sánchez A, Moscoso A, Silva-Rodríguez J, et al. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity. JAMA Neurol. 2023. PMID: 37578787. doi:10.1001/jamaneurol.2023.2560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。